Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00747643 · ClinicalTrials.gov registry record · NA
Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement
A NA study of Tobacco Dependence, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 163
- Enrollment target
- 1
- Study location
NCT00747643: Completed NA study of Tobacco Dependence, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT00747643 is a NA study of Tobacco Dependence that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 163 participants, below the 473-participant average among 28 other Tobacco Dependence trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00747643, a NA study of Tobacco Dependence, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 163 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study was to find out how varenicline works to help people quit smoking. Varenicline, also known as Chantix™, is an U.S. Food and Drug Administration (FDA) approved medication that has been shown to help people quit smoking. This study was trying to evaluate whether varenicline would change the response to smoking and the desire for cigarettes when compared to an inactive placebo control. This was not a quit smoking treatment study, and participants were not asked or required to stop smoking while in this study.
Primary Outcome
Tonic Craving 1 (lowest) to 7 (highest). The Questionnaire of Smoking Urges (QSU), our primary measure of tonic craving, is a 32-item instrument, including 2 separate factor scales that roughly correspond to the desire to smoke for its pleasurable effects (positive reinforcement) or to remove unpleasant feelings of negative affect or withdrawal (negative reinforcement) (Tiffany and Drobes 1991). Following overnight abstinence, each session included assessment of tonic craving, reactivity (includ
Conditions Studied
Interventions
- DRUG placebo
- DRUG varenicline
Study Locations (1)
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-08 |
| Phase | NA |
What the finished NCT00747643 record still lists
NCT00747643 is an interventional study that assigns participants to a tested intervention. The registered 163 participants enrollment target is mid-sized for trials with a published cap, below the 473-participant average among 28 other Tobacco Dependence trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Tobacco Dependence appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00747643 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00747643 about?
NCT00747643 is a clinical study titled "Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement". The purpose of this study was to find out how varenicline works to help people quit smoking. Varenicline, also known as Chantix™, is an U.S. Food and Drug Administration (FDA) approved medication that has been shown to help people quit smoking. This study was trying to evaluate whether varenicline w...
What is the current status of trial NCT00747643?
This trial is currently completed. It is a NA study. The enrollment target is 163 participants. The study started on 2008-09. Estimated completion is 2010-08.
What conditions does trial NCT00747643 study?
This clinical trial studies the following conditions: Tobacco Dependence.
What interventions are being tested in trial NCT00747643?
The interventions under investigation include: placebo (DRUG), varenicline (DRUG).
Who is sponsoring clinical trial NCT00747643?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00747643 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00747643's enrollment target sits among peer trials
163 17th of 28 higher than 12 of 28 other Tobacco Dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tobacco Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harm Reduction for Smokers With Mental Illness
RECRUITING · NA
-
Reach Through Equitable Implementation in Utah
RECRUITING · NA
-
FRESH Delivers: An Innovative Approach to Reducing Tobacco Use Among Rural Smokers
RECRUITING · NA
-
Use of Nicotine Pouches Among Daily Smokers
RECRUITING · NA
-
Smoke-free Home Study in Subsidized Housing
RECRUITING · NA
-
Assessment of Biomarkers in Children to Help Parents Quit Tobacco
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03180268 · 163 participants · Phase 3
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
- NCT04862221 · 163 participants · Phase 2
TReatment for ImmUne Mediated PathopHysiology
- NCT05702229 · 163 participants · Phase 2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT06137118 · 163 participants · Phase 1
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia